Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1174735658
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1245 Wilshire Blvd, Suite 303
Los Angeles, CA, 90017
Phone (213) 977-1214
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
68,365 services
Medicare patients, 2024
521
Average age 74
Drug cost, 2024
$7.6M
2,177 prescriptions
Company payments, 2025
$8,182
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jason S Ho was code J0897 (injection, denosumab, 1 mg), 7,093 times for 38 patients. In total Jason S Ho billed 68,365 services in 99 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 7,093 | 38 | $20.44 | $145K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,267 | 35 | $0.09 | $202 |
| 99214 Office E&M - Established | Office | 1,224 | 361 | $98.86 | $121K |
| J1642 Injection, heparin sodium, (heparin lock flush), per 10 units | Office | 1,040 | 13 | $0.01 | $13.25 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 832 | 15 | $0.07 | $61.97 |
| 85025 Blood Count | Office | 596 | 123 | $7.56 | $4,505 |
| 99213 Office E&M - Established | Office | 439 | 206 | $66.95 | $29K |
| 96372 Injection Administration | Office | 437 | 78 | $11.86 | $5,184 |
| 96127 Behavioral Health Services | Office | 395 | 271 | $3.08 | $1,216 |
| 36415 Venipuncture Blood Collection | Office | 379 | 108 | $8.56 | $3,245 |
| 80053 Clinical Chemistry | Office | 333 | 89 | $10.35 | $3,447 |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 328 | 49 | $0.94 | $310 |
| 96360 Intravenous Infusion, Hydration | Office | 177 | 36 | $27.21 | $4,817 |
| 96367 Intravenous Infusion, Hydration | Office | 173 | 36 | $23.73 | $4,106 |
| 96413 Chemotherapy Administration | Office | 158 | 34 | $114.40 | $18K |
By year: 2022 $722K for 58,201 services; 2023 $635K for 47,945 services; 2024 $1.2M for 68,365 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 596 | 123 | $7.56 | $4,505 |
| 36415 Venipuncture Blood Collection | 379 | 108 | $8.56 | $3,245 |
| 80053 Clinical Chemistry | 333 | 89 | $10.35 | $3,447 |
Medicare prescription drug claims, 2024
In 2024, the drug Jason S Ho prescribed most often to Medicare patients was Letrozole, with 251 prescriptions and refills. In total Jason S Ho wrote 2,177 Medicare prescriptions that cost $7.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 251 | 608 | 70 | $6,212 |
| Procrit Epoetin Alfa | 197 | 197 | 43 | $439K |
| Lupron Depot Leuprolide Acetate | 161 | 187 | 24 | $360K |
| Xtandi Enzalutamide | 107 | 107 | 13 | $1.4M |
| Anastrozole Generic | 101 | 269 | 28 | $1,796 |
| Zarxio Filgrastim-Sndz | 88 | 88 | 28 | $102K |
| Dexamethasone Generic | 78 | 89 | 21 | $1,092 |
| Revlimid Lenalidomide | 68 | 68 | Under 11 | $959K |
| Xgeva Denosumab | 61 | 61 | Under 11 | $191K |
| Prednisone Generic | 58 | 62 | 14 | $199 |
| Hydroxyurea Generic | 46 | 90 | 13 | $1,676 |
| Eliquis Apixaban | 46 | 59 | 12 | $33K |
| Fulvestrant Generic | 41 | 46 | Under 11 | $21K |
| Abiraterone Acetate Generic | 33 | 33 | Under 11 | $79K |
| Ondansetron Odt Ondansetron | 33 | 33 | 25 | $739 |
Brand drugs: - claims; generic drugs: 1,098 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jason S Ho $8,182 ($8,182 in general payments such as food, travel and fees) from 55 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,276.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 34 | $1,276 |
| Janssen Biotech, Inc. JNJ | 30 | $979 |
| AstraZeneca Pharmaceuticals LP AZN | 23 | $606 |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $376 |
| Pfizer Inc. PFE | 16 | $353 |
| Daiichi Sankyo Inc. 4568.T | 17 | $306 |
| Incyte Corporation INCY | 12 | $300 |
| Genzyme Corporation SNY | 7 | $264 |
| Genentech USA, Inc. ROG.SW | 10 | $219 |
| Gilead Sciences, Inc. GILD | 7 | $211 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.